IMMUNEERING CORPORATION - CLASS A COMMON STOCK

Immuneering Granted U.S. Composition of Matter Patent for Highly Differentiated Cancer Drug Candidate Atebimetinib

09 Jul 2025 05:00:00 By Nasdaq GlobeNewswire

Immuneering Reports Positive Overall Survival Data for Atebimetinib (IMM-1-104) from Ongoing Phase 2a Trial in First-Line Pancreatic Cancer Patients

17 Jun 2025 03:00:00 By Nasdaq GlobeNewswire

Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025

16 Jun 2025 05:00:00 By Nasdaq GlobeNewswire

Immuneering to Present at the Jefferies Global Healthcare Conference

29 May 2025 05:01:11 By Nasdaq GlobeNewswire

Immuneering Reports First Quarter 2025 Financial Results and Provides Business Updates

05 May 2025 13:05:00 By Nasdaq GlobeNewswire

Immuneering to Present at the 24th Annual Needham Virtual Healthcare Conference

02 Apr 2025 05:00:00 By Nasdaq GlobeNewswire

Immuneering Corporation Announces Grant of Inducement Award

21 Mar 2025 13:30:09 By Nasdaq GlobeNewswire

Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

20 Mar 2025 13:05:00 By Nasdaq GlobeNewswire

Immuneering Names Dr. Igor Matushansky as Chief Medical Officer

20 Mar 2025 04:00:00 By Nasdaq GlobeNewswire

Immuneering Announces Clinical Supply Agreement with Regeneron Pharmaceuticals to Evaluate IMM-1-104 in Combination with Libtayo® (cemiplimab)

06 Feb 2025 04:00:00 By Nasdaq GlobeNewswire

Immuneering to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

03 Feb 2025 13:05:03 By Nasdaq GlobeNewswire

Immuneering Provides Positive Update on Phase 2a Arm Studying IMM-1-104 in Combination with Modified FOLFIRINOX for First-Line Pancreatic Cancer

13 Jan 2025 05:00:01 By Nasdaq GlobeNewswire

Immuneering Announces Positive Data Update from Three Pancreatic Cancer Arms of Ongoing Phase 2a Trial of IMM-1-104; Plans to Expand Trial with Additional Arms

07 Jan 2025 04:00:00 By Nasdaq GlobeNewswire

Immuneering Launches Pancreatic Cancer Advisory Board

19 Dec 2024 05:00:00 By Nasdaq GlobeNewswire

Immuneering to Present Data from Three Arms of its Ongoing Phase 2a Trial of IMM-1-104 in Early January 2025

17 Dec 2024 05:00:00 By Nasdaq GlobeNewswire

Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma

12 Dec 2024 05:00:00 By Nasdaq GlobeNewswire

Immuneering to Present at the Piper Sandler 36ᵗʰ Annual Healthcare Conference

27 Nov 2024 05:00:00 By Nasdaq GlobeNewswire

Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates

13 Nov 2024 13:05:00 By Nasdaq GlobeNewswire

Immuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic Cancer

15 Oct 2024 05:00:00 By Nasdaq GlobeNewswire

Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients

12 Sep 2024 13:05:00 By Nasdaq GlobeNewswire